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Abstract
The polyneuropathy of juvenile Greyhound show dogs shows clinical similarities to the genetically heterogeneous Charcot-
Marie-Tooth (CMT) disease in humans. The pedigrees containing affected dogs suggest monogenic autosomal recessive
inheritance and all affected dogs trace back to a single male. Here, we studied the neuropathology of this disease and
identified a candidate causative mutation. Peripheral nerve biopsies from affected dogs were examined using semi-thin
histology, nerve fibre teasing and electron microscopy. A severe chronic progressive mixed polyneuropathy was observed.
Seven affected and 17 related control dogs were genotyped on the 50k canine SNP chip. This allowed us to localize the
causative mutation to a 19.5 Mb interval on chromosome 13 by homozygosity mapping. The NDRG1 gene is located within
this interval and NDRG1 mutations have been shown to cause hereditary motor and sensory neuropathy-Lom in humans
(CMT4D). Therefore, we considered NDRG1 a positional and functional candidate gene and performed mutation analysis in
affected and control Greyhounds. A 10 bp deletion in canine NDRG1 exon 15 (c.1080_1089delTCGCCTGGAC) was perfectly
associated with the polyneuropathy phenotype of Greyhound show dogs. The deletion causes a frame shift
(p.Arg361SerfsX60) which alters several amino acids before a stop codon is encountered. A reduced level of NDRG1
transcript could be detected by RT-PCR. Western blot analysis demonstrated an absence of NDRG1 protein in peripheral
nerve biopsy of an affected Greyhound. We thus have identified a candidate causative mutation for polyneuropathy in
Greyhounds and identified the first genetically characterized canine CMT model which offers an opportunity to gain further
insights into the pathobiology and therapy of human NDRG1 associated CMT disease. Selection against this mutation can
now be used to eliminate polyneuropathy from Greyhound show dogs.
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Introduction
Inherited neuropathies comprise all neurological phenotypes
arising from genetic defects that lead to abnormalities of important
peripheral nerve proteins, or impair multisystemic metabolic
pathways [1]. Several subtypes of inherited polyneuropathies were
delineated and classified as hereditary motor and sensory
neuropathies (HMSN), hereditary motor neuropathies (HMN),
and hereditary sensory (and autonomic) neuropathies (HSAN) [2].
These clinically heterogeneous phenotypes affecting the peripheral
nerves are grouped together as Charcot-Marie-Tooth (CMT)
disease. According to nerve conduction studies and/or biopsy
examination, CMT phenotypes are classified into the most
prevalent ‘demyelinating’, the rare ‘axonal’ or ‘neuronal’, and
several ‘mixed’ forms. CMT condition affects an estimated 8 to 41
per 100,000 people worldwide [3]. More than 40 genes with
distinct mutations have been described and most of them lead to
autosomal dominant forms of CMT [4]. Recessive mutations are
less frequent, and many rare CMT forms still await genetic
clarification. Currently, there is no drug therapy for human CMT
disease available. Therefore, studying suitable defined animal
models may be useful for the identification of therapeutic targets
and approaches [5].
Domestic animals constitute an essential complement to rodent
models and are an underutilized resource in biological research
and as a model for human diseases [6]. CMT diseases also occur in
dogs [7] and the dog may represent a better model for human
CMT than genetically engineered mice because of its larger body
size, relatively long life expectancy, and the resulting similarities to
humans. Specific CMT diseases have been described in several
canine breeds including Great Dane [8], Rottweiler [9],
Dalmatian [10], Alaskan Malamute [11], Leonberger [12],
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German Shepherd [7], Italian Spinoni [13], Bouvier des Flandres
[14], Border Collie [15,16], Pyrenean Mountain dog [17], and
Miniature Schnauzer [18]. The underlying genetic defect has not
yet been elucidated for any of the canine CMT forms.
We have observed a severely progressive mixed form of
polyneuropathy, with juvenile onset, in a pedigree of closely
related Greyhound show dogs. We investigated peripheral nerve
biopsies of affected dogs for phenotypic characterization of this
new canine CMT disease. Subsequently, we employed a positional
cloning approach to identify the most likely cause for polyneu-
ropathy in Greyhound show dogs.
Results
Clinical characterization of polyneuropathy
The polyneuropathy of juvenile Greyhound show dogs becomes
clinically apparent between three to nine months of age. Owners
of affected dogs reported exercise intolerance and walking
difficulties such as high stepping gait and bunny hopping in the
early stages of the disease (Video S1). In the later stages, the
disease was characterized by severe muscle atrophy, ataxia and
dysphonia (Video S2). No behavioral abnormalities, retardation or
learning difficulties were observed. On neurological examination,
all dogs were alert, bright, and responsive. Neurological signs of
affected dogs were progressive ataxia and tetraparesis, delayed
proprioceptive placing reactions, hyporeflexia, distal limb muscle
atrophy, and inspiratory stridor (Figure 1A). Depending on the
stage of disease, the gait was moderately to markedly ataxic on all
four limbs and appeared short-strided. Later, however, elbows and
stifles were abducted and the carpus was hyperextended, while
elbow, hip, stifle, and tarsal joints appeared flexed. Trembling and
collapse occurred after exercise. Muscle tone was moderately to
severely reduced, with lack of resistance to passive joint movement
in either direction. Postural reactions seemed unaffected in the
early stages. With disease progression, proprioceptive deficits and
laryngeal involvement occurred. Most strikingly, myotatic reflexes
were reduced or absent. One affected dog had decreased
withdrawal in all four limbs. The cutaneous trunci reflex was
bilaterally absent in another case. Cranial nerve function did not
seem to be affected until the terminal stages of disease. Another
Greyhound developed marked paresis of the intercostal muscles
and diaphragm, leading to respiratory distress. On electromyog-
raphy, a pattern of multifocal spontaneous discharges was
recorded from appendicular muscles in some dogs. Fibrillation
potentials were most common, followed by positive sharp waves
(Figure S1A–C). In particular, the interosseous, cranial tibial, and
gastrocnemius muscles were affected. Motor and sensory nerve
conduction velocities were reduced (Figure S1D). Repetitive nerve
stimulation was unremarkable and compound muscle action
potential amplitude was decreased.
Pathological nerve and muscle findings
All nerve specimens revealed a mild (up to 25%) to marked (25–
50%) reduction in myelinated nerve fibre density associated with
variable endoneurial fibrosis and subperineurial oedema
(Figure 1C). More than 25% of remaining fibres showed marked
to severe loss of circularity due to para- and internodal crenation,
as well as due to outfolded myelin loops at paranodes. The mean
axonal calibre appeared reduced albeit diameter distribution
presented a large scatter of values due to multiple axonal
enlargements in more than 10% of large myelinated teased fibres
at both stereotypic internodal segments (STIN) and paranodes
(Figure 1E and F). Compared to intact axons, these varicosities
stained hyperazurophilic and granular. Electron microscopically,
axonal swellings consisted of axoplasmic dense bodies, distorted
mitochondria, paracrystalline bundles and concentric lamellar
bodies (Figure 1G). Adjacent to these segments adaxonal Schwann
cell compartments contained abundant granulofilamentous inclu-
sions (Figure 1H). Longitudinal sections uncovered multiple
outpouchings of axoplasm extruding into neighbouring uncom-
pacted myelin of inter- and paranodes. Moreover, mild to marked
hyperplasia of the axon-Schwann cell-network was identified in
about 10% of large myelinated fibres, extending deeply into
STINs. Dilation of Schmidt-Lanterman incisures was a frequent
finding and many large myelinated A (alpha) fibres showed ovoid
formation consistent with Wallerian degeneration stage I to III
(Figure 1C and E). In about 5% of fibres with different types of
pathology, there were multiple widened nodes of Ranvier and a
paranodal demyelination was noted in fibres with and without
colocalizing paranodal axon swelling. In rare regenerating fibres,
heminodes and intercalating internodes were seen in clusters.
Severe axonal atrophy went along with paranodal myelin sheath
instability indicated by redundant loops and tomacula (Figure 1I).
Variable degrees of neurogenic atrophy were present within
skeletal muscle samples, consistent with chronic-active denerva-
tion. Atrophy ranged from singular fibres and small fibre groups,
with occasional necrosis, undergoing myophagocytosis to large
groups with scattered, pyknotic nuclear clumps. Other changes
indicating chronic denervation included perimysial lipid accumu-
lation and loss of myelinated nerve fibres within intramuscular
nerve branches.
Genome-wide homozygosity mapping of the
polyneuropathy mutation
We collected blood from dogs affected by polyneuropathy
sampling from the international Greyhound show dog population.
The parents of the 11 affected dogs (8 males, 3 females) were all
healthy. The pedigrees of the 11 affected dogs show many
inbreeding loops (Figure 2 and 3). While the many complex loops
make it difficult to be absolutely certain, the breeding history was
still consistent with a monogenic autosomal recessive inheritance of
polyneuropathy. Remarkably, all affected dogs were related to a
single popular sire born in 1968 on both the maternal and paternal
sides of their respective pedigrees. Under this scenario the
polyneuropathy affected dogs were expected to be identical by
descent (IBD) for the causative mutation and flanking chromosomal
segments. Therefore, we decided to apply a homozygosity mapping
approach to determine the position of the mutation in the canine
genome. We genotyped approximately 50,000 evenly spaced SNPs
in 7 cases and 17 related and unrelated control dogs. We analyzed
the 7 genotyped cases for extended regions of homozygosity with
simultaneous allele sharing. A total of 83 genomic regions larger
than 300 kb fulfilled our search criteria (Figure 4). The size of
homozygous blocks ranged between 0.3 and 19.5 Mb with a mean
size of about 2 Mb and a median of 1.5 Mb. Analyzing the 17
genotyped controls revealed 33 blocks of homozygosity between 0.3
and 7.1 Mb size (Figure 4). Only on CFA 13, in a region containing
538 SNP markers corresponding to a 19.5 Mb interval from 18.7–
38.2 Mb (Figure 4), were all 7 affected genotyped dogs were
homozygous, but the controls were not homozygous.
Identification and characterization of a functional
candidate gene
As the quality of the canine genome annotation is not yet perfect,
we inferred the gene annotation of the mapped interval from the
corresponding human interval. The canine polyneuropathy interval
on CFA 13 corresponds to a segment from 117.2–141.3 Mb on
Canine NDRG1 Mutation
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HSA 8q24. This human interval contains 123 annotated genes
including 14 annotated pseudogenes (NCBI MapViewer, build
37.1). A careful inspection of these genes and database searches of
their presumed function revealed NDRG1 as a functional candidate
gene within the critical interval at 134.3 Mb on HSA 8 and
32.7 Mb on CFA 13, respectively. We performed a mutation
analysis in 2 affected dogs, 2 obligate carriers and 2 control dogs.
This analysis revealed ten polymorphisms in comparison to the dog
Figure 1. Polyneuropathy in Greyhound show dogs.Most consistent findings in affected dogs (A, C, E, G, H, I) compared to healthy controls (B,
D, F). (Scale bar: 100 mm in C and D; 125 mm in E and F; 10 mm in G and H; 17 mm in I). (A, B) General appearance: Affected dogs during ambulatory
stages present with abnormal posture characterized by narrow limb positioning and mildly kyphotic backline (arrow). (C, D) Light microscopic nerve
findings: At advanced disease stages mixed nerves show a drop out of large myelinated A(alpha) fibres, including motor fibres and Ia/b afferents.
Remaining fibres frequently present with axonal atrophy and subsequent myelin sheath adjustment (frame). Multiple myelin ovoids indicate Wallerian
like degeneration (black arrowheads). Hypomyelinated profiles are occasionally seen (white arrowhead). (E, F) Teased nerve fibres: Nerve of affected
dogs showmultifocal paranodal demyelination (red arrowhead), frequently associated with axonal swelling (asterisk). Numerous fibres with and without
other abnormalities are affected bymyelin sheath segmentation (red arrows), consistent with early stage I of Wallerian degeneration. Compare to normal
myelinated nerve fibres with discernible Ranvier’s nodes (RN) and stereotypic internodal segments (STIN). (G) Electron microscopy: Swollen axons (Ax)
show an accumulation of dysmorphic organella, electron dense granules, and lamellated bodies (asterisk). In spite of increased axon diameters the
myelin sheath (MS) most often is disproportionately thin. (H) Electron microscopy: Actual fibre degeneration occasionally starts with axoplasmic
disintegration (Ax) and macrophageal (Mac) myelin stripping from the abaxonal Schwann cell cytoplasm extending along the major dense lines (yellow
arrowhead). (I) Electron microscopy: Fibres with shrunken axons (Ax) show adaxonal myelin sheath protrusion, dyscompaction of the inner myelin layers
(yellow arrow), and accumulation of dysmorphic mitochondria and curvilinear bodies (red arrow).
doi:10.1371/journal.pone.0011258.g001
Canine NDRG1 Mutation
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Figure 2. Pedigrees of sampled Greyhound show dogs with polyneuropathy. DNA samples were available only from GY numbered dogs.
Animals genotyped on the SNP chip are indicated by asterisk. The genotypes for the NDRG1 exon 15 deletion are given below the symbols. Due to
the very close relationships four single pedigrees are shown, where some individuals indicated with identical numbers are represented in multiple
pedigrees (also in Figure 3).
doi:10.1371/journal.pone.0011258.g002
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reference genome sequence, including 9 SNPs and a single 10 bp
deletion (Table S1). Of these polymorphisms only the deletion
within exon 15 (c.1080_1089delTCGCCTGGAC, Figure 5)
showed perfect association to the polyneuropathy phenotype. We
genotyped additional dogs for the mutation and found perfect
concordance between the presence of the deletion and the
polyneuropathy phenotype in all available affected dogs, while the
deletion was present in the heterozygous state in all obligate carriers
(Figure 2 and 3; Table 1). Four grandmothers, a single grandfather,
and 8 out of 11 healthy full-sibs of affected dogs were also
heterozygous. None of 245 unrelated healthy Greyhound show dogs
had the homozygous del/del genotype, but 62 (,25%) were also
carriers. The mutant allele was absent from 112 Greyhound racing
dogs, and was also not present in any of the 91 control dogs from
different breeds including 7 other types of sight hounds (Table 1).
Analysis of NDRG1 expression in peripheral nerve tissue
RT-PCR on peripheral nerve cDNA confirmed that the NDRG1
mRNA is normally spliced in Greyhounds with polyneuropathy.
We sequenced the cDNA from 3 affected dogs and it contained the
10 bp deletion in a homozygous state confirming that the mutant
mRNA is expressed. Semi-quantitative RT-PCR revealed evi-
dence that the expression level of the mutant NDRG1 RNA
transcript is considerably reduced in comparison to wild-type
control dogs (Figure 6). The deletion is predicted to result in a
frameshift beginning with amino acid residue 361. Notably, the
mutation does not lead to premature termination of translation but
predicts a C-terminal mutated protein (p.Arg361SerfsX60) that is
longer than the wild-type protein (384 amino acid residues). To
evaluate the functional consequences of this deletion we performed
a western blot on protein extracts from neural tissue of an affected
dog and a healthy control dog to investigate whether the predicted
longer mutant NDRG1 protein is expressed. The western blot of
the control dog showed a strong band of the expected size for the
NDRG1 protein. However, in contrast to our initial hypothesis, no
NDRG1 specific band was detected in neural tissue of the
homozygous mutant affected Greyhound show dog (Figure 7).
Therefore the transcript was present, but appeared not to be
translated to protein.
Discussion
Most known neuropathies in dogs manifest in adolescence or
adulthood [7]. However, the juvenile polyneuropathy in Grey-
Figure 4. Genome-wide homozygosity mapping of the polyneuropathy mutation. After genotyping approximately 50,000 fairly uniformly
distributed SNP markers homozygous blocks were identified independently across 7 affected and 17 control dogs. Note that only on canine
chromosome (CFA) 13 a unique large homozygous block was identified in the cases.
doi:10.1371/journal.pone.0011258.g004
Figure 3. Pedigrees of sampled Greyhound show dogs with polyneuropathy. DNA samples were available only from GY numbered dogs.
Animals genotyped on the SNP chip are indicated by asterisk. The genotypes for the NDRG1 exon 15 deletion are given below the symbols. Due to
the very close relationships four single pedigrees are shown, where some individuals indicated with identical numbers are represented in multiple
pedigrees (also in Figure 2).
doi:10.1371/journal.pone.0011258.g003
Canine NDRG1 Mutation
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hounds stands out by an early onset of about three to nine months
of age. After clinical signs appeared none of the animals survived
longer than ten months. If not euthanized earlier on request of the
owners, progression of laryngeal paresis/paralysis and phrenic
neuropathy is going to inflict lethal consequences. All dogs of this
study suffered from a polyneuropathy that could be classified as
mixed or predominantly axonal disease based on evidence of
axonal dystrophy from electron microscopy.
The Greyhound is a breed of hunting dogs that has been bred
primarily for chasing game. Nowadays, the vast majority of
Greyhounds are bred for professional racing, but partially also as
pedigree show dogs and family pets. Although they officially
belong to a single breed, breeding lines of show and racing
Greyhounds have been almost completely separated for 60 years.
It seems likely that the deleterious mutation arose in the show dog
population, as no carrier of the NDRG1 mutation has been
Figure 5. NDRG1 mutation analysis. (A) Canine NDRG1 gene structure. (B) Electropherograms of the NDRG1 c.1080_1089delTCGCCTGGAC
mutation. Representative sequence traces of PCR products amplified from genomic DNA of 3 dogs with the different genotypes are shown. The
presence of the mutation can be directly visualized by fragment size analysis of a fluorescently labeled PCR product containing the mutation. Note
that the mutant allele with the 10 bp-deletion is present in homozygous form only in polyneuropathy affected dogs.
doi:10.1371/journal.pone.0011258.g005
Canine NDRG1 Mutation
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identified among the racing dog variety. The fact, that about a
quarter of all genotyped Greyhound show dogs carries the
mutation for polyneuropathy, might be explained by an intensive
use of particular male carriers selected for desired show traits
during the establishment and/or expansion of the Greyhound
show dog population. The founding mutation presumably
happened at least nine to eleven generations before the reported
cases occurred (Figure 2). As shown for the affected dogs, also all
genotyped carriers of the NDRG1 mutation can be traced back to
the popular sire born in 1968. If this popular Greyhound show sire
disseminated the deleterious mutation, subsequent inbreeding
among the descendants increased the likelihood of polyneuropathy
emerging. The observed high allele frequency (,25%) of the
polyneuropathy mutation together with the high number of
homozygous SNPs (,60%) in the genotyped dogs including
affected dogs and controls, suggest a high level of inbreeding
within the Greyhound show dog population. This confirms the
general observation, that the population structure of modern dogs
makes them particularly useful for positional cloning studies, as a
single breed may resemble recombinant inbred lines [19]. This
reduced genetic diversity within dog breeds leads to large
haplotype blocks, as detected in the examined Greyhound dogs
in this study.
The aim of this study was to identify the gene responsible for
polyneuropathy of Greyhound show dogs. Homozygosity mapping
identified a large segment on CFA 13. In comparison to a recent
study, where the causative gene for recessively inherited
osteogenesis imperfecta in Dachshunds was mapped to a unique
homozygous chromosome segment of 5.8 Mb after genotyping of
only 5 affected dogs on the 50k canine SNP chip [20], we here
identified several extended Mb regions of homozygosity in the 7
affected dogs including the longest of 19 Mb containing the
mutation. The long region surrounding the mutation suggests that
the polyneuropathy mutation is quite young, whereas the high
number of homozygous regions in both cases and controls suggests
a generally inbred population. The fact that healthy controls
shared some of these homozygous segments and had identical
alleles helped us to focus on the chromosome segment of 19.5 Mb
on CFA 13. We note that the mapping of older mutations may
require many more affected dogs, because the associated IBD
haplotype is usually much smaller, due to independent recombi-
nation events over several generations [19]. Still, this study shows
once again, that the use of genome-wide canine SNP data enables
very efficient positional cloning projects of Mendelian traits, even
if only very few samples are available.
The mapped polyneuropathy interval on CFA 13 contained a
compelling functional candidate gene, NDRG1. This gene is known
to be implicated in recessive inherited human Charcot-Marie-
Tooth disease type 4D (CMT4D; hereditary motor and sensory
neuropathy-Lom) [21]. In addition, Ndrg1-deficient mice have
shown that NDRG1 is essential for maintenance of the myelin
sheaths in peripheral nerves [22]. Histological analysis of the
sciatic nerve of Ndrg1-deficient mice showed degenerated with
demyelination at about five weeks [22]. Although myelination of
Schwann cells in the sciatic nerve was normal for two weeks after
birth, subsequently, Ndrg1-deficient mice showed progressive
muscle weakness, especially in the hind limbs. As the age of onset,
the clinical course of the disease, and the described nerve
pathology in polyneuropathy affected Greyhound show dogs is
highly similar to CMT4D affected children and Ndrg1-deficient
mice, we analyzed the canine NDRG1 for possible mutations. DNA
Table 1. Association of the NDRG1 mutation with the
polyneuropathy phenotype.
Breed free carrier* affected total
Greyhound (show) 189 84 10 283
Greyhound (racing) 112 112
Afghan Hound 2 2
Borzoi 1 1
Galgo Espan˜ol 1 1
Italian Greyhound 1 1
Irish Wolfhound 1 1
Saluki 1 1
Whippet 9 9
other breeds (n = 75) 75 75
*Parents of affected offspring were classified as obligate carriers (n = 12).
doi:10.1371/journal.pone.0011258.t001
Figure 6. RT-PCR of NDRG1 expression in peripheral nerve biopsies. A strong band of the expected size of wild-type NDRG1 transcript was
amplified from two 2 control dogs. Three polyneuropathy affected Greyhound show dogs yielded clearly weaker band intensities. In comparison, the
detected beta 2-microglobulin gene expression was quite similar between all samples. (M: 100 bp DNA ladder).
doi:10.1371/journal.pone.0011258.g006
Canine NDRG1 Mutation
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sequencing revealed a 10 bp deletion in the NDRG1 gene, which is
perfectly associated with the polyneuropathy phenotype in
Greyhound show dogs. We confirmed the presence of this
mutation on the genomic DNA and mRNA level. Interestingly,
we detected a significantly reduced steady-state abundance of
NDRG1 transcript in affected nerves compared to the situation in
healthy dogs. Nonsense-mediated decay (NMD) selectively recog-
nizes and degrades mRNAs whose open reading frame is
truncated by a premature translation termination codon [23]. As
the canine NDRG1 deletion leads to a different and longer terminal
portion of the protein, NMD seems to be unlikely as the causative
mechanism for this observation, thus indicating the existence of
alternative RNA decay mechanisms.
While it was unclear whether the mutant protein is actually
expressed, we speculated that due to the frameshift, any mutant
protein produced will contain 61 altered amino acids. Thus,
mutant protein might be misfolded and exhibit protein dysfunc-
tion, and also could potentially interfere with normal cellular
function. A database search for possible identical proteins revealed
no results and the Western blot analysis detected no mutant
protein in peripheral nerve from a polyneuropathy affected dog,
likely due to the absence of the protein. The normal cellular
function of the altered NDRG1 may not be maintained. Taken
together, we think that the most likely explanation for the
polyneuropathy phenotype in affected Greyhound show dogs is
lack of NDRG1 caused by the 10 bp deletion. The analysis of
NDRG1 expression using an antibody which is predicted to detect
the wild-type and the mutant protein in neural tissue extracts of an
affected and a healthy control dog confirmed our hypothesis.
Obviously, a complete lack of NDRG1 in homozygous mutant
dogs causes the severe course of the disease, as previously reported
in Ndrg1-deficient mice [22].
Our finding of a NDRG1 mutation in dogs with polyneuropathy
provides a valuable model for human medicine possibly useful for
the investigation of the pathogenesis and therapeutic trials. The
naturally occurring polyneuropathy dog model may represent a
better model for human CMT4D than Ndrg1-deficient mice
because of the dog’s body size and structure and the resulting
similarity to the human situation. In addition, the longer life
expectancy of dog allows for investigations over a longer time
period. Dogs have the additional advantages of being economic to
maintain and having been bred for easy management. Moreover,
a high level of expertise in reproductive technology and veterinary
care is available for them.
In conclusion, by positional cloning we have identified the
10 bp deletion in the canine NDRG1 gene as the most likely
causative mutation for polyneuropathy in Greyhound show dogs.
This result allows careful eradication of this genetic disease from
the worldwide Greyhound breeding population. Our study also
provides a defined animal model for similar human hereditary
CMT diseases and confirms NDRG1 critical function for
myelination of peripheral nerves.
Materials and Methods
Animals
We collected samples from polyneuropathy affected Greyhound
show dogs (n = 10), their healthy littermates (n = 11), sires (n = 6),
dams (n= 6), and grandparents (n = 6). Affected dogs derived from
Sweden, Denmark, Latvia, France, and Germany. All samples
were submitted from private dog owners for research purpose only
in accordance with the institutional ethical guidelines. Parents of
affected offspring were classified as obligate carriers (n = 14). We
also collected 245 not closely related healthy Greyhound show
dogs and 112 Greyhound racing dogs resulting in a total of 395
samples from the Greyhound breed. Furthermore, we sampled 16
unrelated control dogs from seven sighthound breeds, which are
greyhound shaped dogs (Afghan Hound (n= 2), Borzoi (n = 1),
Galgo Espan˜ol (n = 1), Italian Greyhound (n = 1), Irish Wolfhound
(n= 1), Saluki (n = 1), Whippet (n = 9)) and 75 dogs from 75
different breeds for the genotyping of the NDRG1 exon 15
deletion.
Clinical characterization of polyneuropathy
Six affected Greyhound show dogs underwent a complete
neurological examination according to standardized protocols by
different veterinary neurologists because of weakness and progres-
sive gait abnormalities of insidious onset between three to nine
months within the first year of life. Electrophysiological evalua-
tions were performed in 5 affected dogs under varying types of
Figure 7. Western Blot analysis of NDRG1 protein expression in
peripheral nerve biopsies. A strong band of the expected size of
wild-type NDRG1 protein (41.7 kDa) was detected in the protein sample
from the healthy control dog. Protein extract from the nerve of a
polyneuropathy affected dog yielded no specific band. In comparison, a
band of the expected size of beta-actin (ACTB, 45 kDa) was detected in
both samples.
doi:10.1371/journal.pone.0011258.g007
Canine NDRG1 Mutation
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general anaesthesia. An electromyogram was recorded from
virtually all muscles of front and hind limbs, paraxial musculature
and several muscles of the head. Nerve conduction studies and
repetitive nerve stimulation was carried out on ulnar, peroneal,
and tibial nerves.
Histopathological examination of nerve and muscle
biopsies
Nerve and muscle biopsies were obtained from four animals.
Muscle samples were either snap-frozen in isopentane cooled in
liquid nitrogen or immersed in 10% neutral-buffered formalin for
paraffin embedding. Cryosections were stained with haematoxy-
lin-eosin (HE), modified Gomori trichrome stain, oil red O, and
periodic acid Schiff reaction. Moreover, fibre type differentiation
was achieved through ATPase reaction and enzyme histochem-
istry for reduced NADH-TR. Formalin-fixed muscle samples
underwent HE and Goldner’s trichrome staining. Obtained nerve
samples were prepared under a stereolupe and fixed by 2.5%
glutaraldehyde in 0.1 M Soerensen’s phosphate buffer. Thereaf-
ter, fascicles underwent OsO4 impregnation and were either
embedded in epoxy resin, or immersed in glycerol for single nerve
fibre teasing. Plastic embedded material gave rise to semi- and
ultrathin sections, with the latter analysed through transmission
electron microscopy in a Zeiss EM 10H at 80 kV and a
magnification from61,700 to680,000.
DNA and RNA extraction
Genomic DNA was isolated from blood or tissue using the
Nucleon Bacc2 kit (GE Healthcare). Total RNA was isolated using
Trizol reagent (Invitrogen) and DNaseI (Roche) digested accord-
ing to the manufacturer’s instructions.
Genome-wide homozygosity mapping of the
polyneuropathy mutation
Genomic DNA from 7 cases and 17 related control dogs was
genotyped on the canine Affymetrix version 2 single nucleotide
polymorphism (SNP) genotyping microarray (49,663 SNPs). The
results were analyzed with PLINK [24]. After removing 11,604
SNPs with low genotyping success (failed calls .0.3) the average
genotyping rate per individual was 81%. A total of 15,034 out of
the remaining 38,059 SNPs were polymorphic. Two small nuclear
families segregating for polyneuropathy were included to check
SNPs for Mendelian inheritance. To identify extended homozy-
gous regions with allele sharing across cases and controls, the
following PLINK options were used: –dog –homozyg-kb 100 –
homozyg-gap 2500 –homozyg-density 250 –homozyg-match 0.95
–homozyg-window-snp 20 –homozyg-window-missing 5 –homo-
zyg-group –maf 0 –max-maf 1.0 –geno 0.3 –hwe 0 –mind 0.3. All
given positions correspond to the CanFam2.0 genome assembly
[25]. The corresponding human chromosome segment was
identified by BLASTN searches of canine SNP flanking sequences
to the human genome sequence.
Mutation analysis of canine NDRG1
The established canine cDNA sequence was used for genomic
sequence alignment with the current CFA 13 sequence to
characterize the exact gene structure (Figure 4). Primers for the
amplification of each of the 15 NDRG1 coding exons with flanking
intronic regions were designed with the software Primer3 (http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) after mask-
ing repetitive sequences with RepeatMasker [26]. Primer sequenc-
es and PCR conditions are available on request. For the mutation
analysis PCR products were amplified of 2 affected and 2
unrelated healthy dogs using AmpliTaqGoldH360 DNA polymer-
ase (Applied Biosystems). The subsequent re-sequencing of the
PCR products was performed after rAPid alkaline phosphatase
(Roche) and exonuclease I (New England Biolabs) treatment using
both PCR primers with the ABI BigDye Terminator Sequencing
Kit 3.1 (Applied Biosystems) on an ABI 3730 genetic analyzer.
Sequence data were analyzed with Sequencher 4.9 (GeneCodes).
Fragment size analyses for the genotyping of the NDRG1 exon 15
deletion were also performed on an ABI 3730 capillary sequencer
and analyzed with the GeneMapper 4.0 software (Applied
Biosystems).
RT-PCR
Aliquots of 500 ng total RNA were reverse transcribed into
cDNA using 20 pmol (T)24V primer and Superscript II reverse
transcriptase (Invitrogen). Two microliters of the cDNA were used
as a template in RT-PCR.
Western blot analysis
For Western blot analysis, peripheral nerve biopsies were
homogenized in extraction buffer (20 mM Tris, 2% Triton-6100,
20% 56 Laemmli buffer) and protein concentration was
determined by BCA assay. Equal amounts of proteins were
loaded per lane on 10% SDS-polyacrylamide minigel. The
following primary antibodies were used: rabbit polyclonal
antibody against human NDRG1 (Sigma-Aldrich HPA006881,
immunogen corresponded with 98% identity to aa163-284 of
canine NDRG1), and rabbit monoclonal antibody against ACTB
(Cell Signaling Technology).
Supporting Information
Table S1 NDRG1 polymorphisms.
Found at: doi:10.1371/journal.pone.0011258.s001 (0.06 MB
PDF)
Figure S1 Selected electrophysiological registrations from a 9-
month-old Greyhound affected by polyneuropathy.
Found at: doi:10.1371/journal.pone.0011258.s002 (0.13 MB
PDF)
Video S1 Polyneuropathy affected Greyhound show dog (age of
3 month).
Found at: doi:10.1371/journal.pone.0011258.s003 (3.08 MB
MOV)
Video S2 Polyneuropathy affected Greyhound show dog (age of
9 month).
Found at: doi:10.1371/journal.pone.0011258.s004 (9.67 MB
MOV)
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